neuroFix Therapeutics Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 1

neuroFix Therapeutics General Information


Developer of therapeutic products. The company develops NFC-1 a non-stimulant metabotropic glutamate receptor for the treatment of mGluR network mutation positive attention deficit hyperactivity disorder and neuropsychiatric symptoms in USA.

Contact Information

Ownership Status
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • DE
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

neuroFix Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore neuroFix Therapeutics‘s full profile, request access.

Request a free trial

neuroFix Therapeutics Patents

neuroFix Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-1199297-A Spinal osteosynthesis device Inactive 05-Mar-1996 00000000000
EP-0884979-A1 Spinal osteosynthesis device Inactive 05-Mar-1996 00000000000
FR-2745707-B1 Spinal osteosynthesis device Inactive 05-Mar-1996 00000000000
FR-2745707-A1 Spinal osteosynthesis device Active 05-Mar-1996 A61B17/7026 0

neuroFix Therapeutics Executive Team (1)

Name Title Board Seat Contact Info
Hakon Hakonarson Ph.D Founder
To view neuroFix Therapeutics’s complete executive team members history, request access »